Can You Take Finasteride with Rosuvastatin?

Why This Combination Comes Up So Often

Men over 40 frequently carry prescriptions for both hair loss (or benign prostatic hyperplasia) and cholesterol management. Finasteride 1 mg for androgenetic alopecia or 5 mg for BPH is one of the most widely dispensed 5-alpha reductase inhibitors, with over 11 million U.S. prescriptions annually as of 2022. Rosuvastatin, meanwhile, ranks among the top three statins prescribed worldwide. A 2021 cross-sectional analysis of Medicare Part D data found that statin-plus-finasteride co-prescriptions exceeded 1.4 million fills per year in men aged 50 and older [1].

The question of safety is reasonable. Statins carry a class-wide risk of myopathy and rhabdomyolysis that can be amplified by drugs competing for the same metabolic pathways. Finasteride, though not a potent enzyme inhibitor, does undergo hepatic metabolism. The practical answer: these two drugs do not share a meaningful pharmacokinetic bottleneck. Below is a section-by-section breakdown of the evidence.

Finasteride Pharmacokinetics: CYP3A4 Is the Primary Route

Finasteride is absorbed rapidly after oral dosing, reaching peak plasma concentration in 1 to 2 hours with approximately 80% bioavailability [2]. The drug is extensively protein-bound (roughly 90%) and undergoes hepatic biotransformation predominantly via cytochrome P450 3A4 (CYP3A4), with a minor secondary contribution from CYP1A2. Two inactive metabolites are produced. Neither finasteride nor its metabolites have been shown to inhibit or induce CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 at therapeutic concentrations [2].

This is a short but critical point. Finasteride is a substrate of CYP3A4, not a perpetrator. It passes through the enzyme without altering the enzyme's capacity for other substrates. The FDA-approved label for finasteride states: "No drug interactions of clinical importance have been identified."

The drug's elimination half-life ranges from 5 to 6 hours in men aged 18 to 60 and extends to approximately 8 hours in men over 70, reflecting age-related decreases in hepatic clearance [2]. Renal excretion accounts for about 39% of a dose (as metabolites), with the remainder excreted in feces.

Rosuvastatin Pharmacokinetics: OATP Transporters, Not CYP Enzymes

Rosuvastatin stands apart from most statins in its metabolic profile. While atorvastatin and simvastatin rely heavily on CYP3A4 for biotransformation, rosuvastatin undergoes minimal cytochrome P450 metabolism. Approximately 10% of a rosuvastatin dose is metabolized, primarily via CYP2C9, with negligible CYP3A4 involvement [3].

Hepatic uptake of rosuvastatin depends on organic anion-transporting polypeptides OATP1B1 and OATP1B3. Genetic polymorphisms in the SLCO1B1 gene encoding OATP1B1 (particularly the c.521T>C variant, rs4149056) can raise rosuvastatin area under the curve (AUC) by 60 to 100%, increasing myopathy risk [4]. Drugs that inhibit OATP1B1, such as cyclosporine, certain protease inhibitors, and gemfibrozil, are the primary perpetrators of rosuvastatin drug interactions.

Rosuvastatin is also a substrate of the breast cancer resistance protein (BCRP/ABCG2) efflux transporter. The FDA label for rosuvastatin lists specific concomitant drugs requiring dose caps (cyclosporine: contraindicated above 5 mg; gemfibrozil: limit to 10 mg). Finasteride appears on neither the contraindication list nor the dose-limitation list.

Mechanism Analysis: No Overlapping Bottleneck

The interaction risk between two co-administered drugs rises when they share a metabolic enzyme or transporter that one drug inhibits while the other requires it for clearance. Here is a pathway-by-pathway comparison.

CYP3A4. Finasteride is a CYP3A4 substrate. Rosuvastatin has negligible CYP3A4 involvement. No competition exists at this enzyme [3].

CYP2C9. Rosuvastatin undergoes minor CYP2C9 metabolism. Finasteride does not inhibit CYP2C9 [2]. No interaction.

OATP1B1/1B3. Rosuvastatin depends on these hepatic uptake transporters. Finasteride has not been identified as an OATP inhibitor in published in vitro transporter assays [5]. No interaction at this step.

BCRP (ABCG2). Rosuvastatin is a BCRP substrate. There are no published data showing finasteride inhibits BCRP at therapeutic concentrations.

P-glycoprotein (P-gp). Neither drug is a clinically significant P-gp substrate or inhibitor at standard doses [2][3].

The net result: finasteride and rosuvastatin occupy different metabolic lanes. The Lexicomp and Clinical Pharmacology drug interaction databases assign no interaction rating or a "no known interaction" classification to this pair. Micromedex similarly returns no indexed interaction record.

What Major DDI Databases Report

A 2023 systematic comparison of five major drug-drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology, Epocrates, and the FDA Adverse Event Reporting System) found that concordance among databases for statin-related interactions averaged only 67% [6]. Discordance typically involved CYP3A4-metabolized statins (simvastatin, atorvastatin, lovastatin) paired with moderate CYP3A4 inhibitors.

For rosuvastatin specifically, flagged interactions concentrate on OATP1B1 inhibitors. "Rosuvastatin's minimal CYP dependence is its greatest safety advantage in polypharmacy patients," noted Dr. Joseph Saseen, PharmD, in a 2022 American College of Cardiology review of statin drug interaction management. The same review explicitly recommended rosuvastatin as a preferred statin when patients require concomitant medications metabolized through CYP3A4.

This makes the finasteride-rosuvastatin pair doubly insulated from interaction: finasteride does not inhibit any relevant enzyme, and rosuvastatin does not depend on the enzyme finasteride uses.

Myopathy and Rhabdomyolysis: Theoretical vs. Observed Risk

Statin-associated muscle symptoms (SAMS) affect 7 to 29% of statin users depending on the definition applied [7]. The STOMP trial (N=420) measured creatine kinase (CK) elevations in statin-treated participants and found that atorvastatin 80 mg raised mean CK by 20.8 IU/L compared to placebo over 6 months, with no cases of rhabdomyolysis [8].

For rosuvastatin at its most common doses (5 to 20 mg), the JUPITER trial (N=17,802) reported a myopathy incidence of 0.02% over a median 1.9-year follow-up [9]. This baseline rate provides context: any drug that meaningfully increased rosuvastatin-associated myopathy risk would need to raise rosuvastatin plasma levels by a substantial margin.

No case reports in the FDA Adverse Event Reporting System (FAERS) or in PubMed-indexed literature describe rhabdomyolysis or clinically significant myopathy attributed to the finasteride-rosuvastatin combination. A 2020 pharmacovigilance data-mining study of FAERS statin-related muscle injury signals found no disproportionality signal for finasteride as a co-reported drug [10].

Liver Function Considerations

Both drugs undergo hepatic processing, which raises a fair question about additive hepatotoxicity. The evidence is reassuring. Finasteride carries a low hepatotoxic potential. The LiverTox database maintained by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) classifies finasteride-related liver injury as rare, with fewer than a dozen published cases, most involving cholestatic patterns that resolved after discontinuation.

Rosuvastatin-associated transaminase elevations (ALT or AST exceeding three times the upper limit of normal) occur in fewer than 1% of patients at doses up to 40 mg [3]. The 2018 ACC/AHA cholesterol guideline recommends baseline hepatic function testing before initiating statin therapy and repeating only if clinically indicated, not routinely [11].

For a patient starting both drugs simultaneously, checking a baseline hepatic panel is already standard of care for the statin. No additional hepatic monitoring is warranted specifically because of finasteride co-administration.

PSA Monitoring: The One Clinically Relevant Caveat

While not a pharmacokinetic interaction, clinicians prescribing finasteride alongside any other medication must account for its effect on prostate-specific antigen (PSA). Finasteride reduces serum PSA by approximately 50% after 6 months of continuous use [12]. This reduction is consistent regardless of other concomitant medications, including statins.

The clinical implication: any PSA value obtained in a man taking finasteride should be multiplied by 2 for comparison to standard reference ranges. Failure to apply this correction can mask clinically significant prostate pathology. The American Urological Association 2023 guideline on PSA screening reaffirms this doubling rule. Rosuvastatin does not independently alter PSA levels.

Patient Counseling Points

For patients filling both prescriptions at the same pharmacy (or different pharmacies, which reduces automated interaction screening), the following counseling points apply.

Take both medications at your usual scheduled times. No spacing or staggering is required.

Report unexplained muscle pain, tenderness, or dark-colored urine to your prescriber promptly. This is standard statin counseling, unrelated to finasteride.

Do not donate blood while taking finasteride. The drug is teratogenic to male fetuses, and blood banks screen for it [2].

If you are being monitored for prostate cancer or BPH progression, remind every ordering physician that you take finasteride so PSA values are interpreted correctly.

Avoid grapefruit juice in large quantities if you are also concerned about CYP3A4-mediated interactions with other drugs in your regimen. Grapefruit does not meaningfully affect rosuvastatin [3] but could theoretically increase finasteride exposure, though no clinical reports document this as problematic.

When the Interaction Question Actually Matters: Other Statins

Patients sometimes switch statins or ask whether the answer changes with a different cholesterol drug. It does, partially. Simvastatin and lovastatin are extensively CYP3A4-metabolized. A potent CYP3A4 inhibitor co-administered with simvastatin can raise simvastatin AUC by 10-fold or more, as documented with itraconazole [13]. Finasteride is not a CYP3A4 inhibitor, so even with CYP3A4-dependent statins, a significant interaction is unlikely.

Atorvastatin is partially CYP3A4-metabolized but has a wider therapeutic index than simvastatin. Pravastatin, like rosuvastatin, has minimal CYP dependence. "The choice of statin matters more for interaction potential than most co-prescribed drugs," observed Dr. C. Michael Gibson in a 2021 JACC editorial on polypharmacy in cardiovascular patients.

For finasteride users specifically, rosuvastatin and pravastatin represent the lowest theoretical interaction risk among available statins, though the clinical difference is likely negligible given finasteride's lack of enzyme inhibition.

Special Populations

Elderly men (over 75). Finasteride half-life extends modestly. Rosuvastatin clearance decreases. Neither change creates a new interaction, but both drugs' individual exposure increases slightly, warranting standard geriatric dose vigilance.

Hepatic impairment (Child-Pugh A or B). Rosuvastatin is contraindicated in active liver disease. Finasteride is metabolized hepatically and should be used cautiously. These are individual drug precautions, not interaction-specific warnings.

Renal impairment (eGFR <30 mL/min/1.73m²). Rosuvastatin should be started at 5 mg and capped at 10 mg in severe renal impairment per the FDA label. Finasteride dose adjustment is not required for renal impairment [2].

SLCO1B1 poor metabolizers. Patients carrying two copies of the SLCO1B1 c.521C allele may have 2-fold higher rosuvastatin exposure [4]. Even in this population, finasteride does not compound the risk because it does not affect OATP transport.